Required Line For Here. Required Line For Here.Required Line For Here. Required Line For Here. Required Line For Here. Required Line For Here.

Company Profile

CAPLIN POINT LABORATORIES LTD.

NSE : CAPLIPOINTBSE : 524742ISIN CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE401.40-11.6 (-2.81 % )
PREV CLOSE (Rs.) 413.00
OPEN PRICE (Rs.) 410.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 401.40 (2 )
VOLUME 4395
TODAY'S LOW / HIGH (Rs.)399.00 410.00
52 WK LOW / HIGH (Rs.)304.75 535
NSE401.65 -8.7 (-2.12 % )
PREV CLOSE(Rs.) 410.35
OPEN PRICE (Rs.) 408.00
BID PRICE (QTY) 401.65 (24 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 16646
TODAY'S LOW / HIGH(Rs.) 400.00 411.35
52 WK LOW / HIGH (Rs.)296.05 537.9

Company News

Date Heading Details
17-Jun-2019 USFDA completes inspection at Caplin Point Laboratories' Steriles Injectable site <p align="justify">US Food and Drug Administration (USFDA) has completed inspection at Caplin Steriles' Injectable site at Gummidipoondi between June 6 and June 14, 2019. Caplin Steriles is a Wholly Owned Subsidiary of Caplin Point Laboratories.</p><p align="justify">At the end of this scheduled GMP inspection, there were only two observations. The company believes these to be of procedural in nature and the corrective and preventive actions for these observations will be presented to the US FDA shortly. The observations made were not repeat observations or related to data integrity.</p><p align="justify">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations. <br></p>
31-May-2019 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS INTIMATION OF ALLOTMENT OF EQUITY SHARES UNDER EMPLOYEE STOCK OPTION PLAN -2015.
22-May-2019 Board recommends Dividend Caplin Point Laboratories Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 22, 2019, inter alia, has recommended a dividend of Rs. 2.20 (110%) per equity share of Rs. 2/- each for the financial year ended March 31, 2019.
13-May-2019 Caplin Point gets Colombia's INVIMA approval for sterile injectables <p align="justify">Caplin Point Laboratories has received Colombia's INVIMA approval for its small volume sterile injectable division at Puducherry. The site inspection of Unit-1 was completed on May 10 and found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). The facility is capable of manufacturing Liquid injectables in Vials, Ampoules, Lyophilized Vials and Pre-Filled Syringes, amongst other dosage forms.</p><p align="justify">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations. <br></p>
11-Apr-2019 Announcement under Regulation 30 (LODR)-Cessation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, we wish to inform BSE that Dr Philip Ashok Karunakaran has tendered his resignation from the position of Whole-time Director and from the Board due to health reasons, effective from the close of business working hours on April 10, 2019. The Company wishes to place on record the valuable contributions made by Dr Philip Ashok Karunakaran during his tenure as a Whole-time Director. We further wish to inform that the Company has appointed Mr M Panjatcharam (who was previously the Head of R&D - Quality at Sun Pharmaceuticals Industries Limited) as a Whole-time Director of Caplin Steriles Limited (Wholly Owned Subsidiary Company) and as Head of Quality, R&D and Operations for the Company's regulated markets injectable business, including US FDA approved injectable plant and DSIR recognised R&D Units CP4 & CP 5, which is now Caplin Steriles Limited. Mr. Panjatcharam is an Analytical Chemistry Post Graduate and a Pharma Professional with more than 25 years of experience in various Quality Control, Assurance and R&D Functions in API, Formulation, Pharma R&D, Biologics with Strong Exposure on cGMP Requirements & Designing of Product Quality Attributes on Injectables, Ophthalmics, Inhalers, Oncology Products, Potent Molecules and Peptides. He was Involved in many successful regulated inspections of USFDA, EUGMP, MHRA, MCC, TGA, ANVISA and BFRM. His past assignments include Quality leadership roles in Dr.Reddy's Laboratories Limited, Dabur Research Foundation, Aurobindo Pharma Limited etc.
11-Apr-2019 Announcement under Regulation 30 (LODR)-Cessation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, we wish to inform BSE that Dr Philip Ashok Karunakaran has tendered his resignation from the position of Whole-time Director and from the Board due to health reasons, effective from the close of business working hours on April 10, 2019. The Company wishes to place on record the valuable contributions made by Dr Philip Ashok Karunakaran during his tenure as a Whole-time Director. We further wish to inform that the Company has appointed Mr M Panjatcharam (who was previously the Head of R&D - Quality at Sun Pharmaceuticals Industries Limited) as a Whole-time Director of Caplin Steriles Limited (Wholly Owned Subsidiary Company) and as Head of Quality, R&D and Operations for the Company's regulated markets injectable business, including US FDA approved injectable plant and DSIR recognised R&D Units CP4 & CP 5, which is now Caplin Steriles Limited. Mr. Panjatcharam is an Analytical Chemistry Post Graduate and a Pharma Professional with more than 25 years of experience in various Quality Control, Assurance and R&D Functions in API, Formulation, Pharma R&D, Biologics with Strong Exposure on cGMP Requirements & Designing of Product Quality Attributes on Injectables, Ophthalmics, Inhalers, Oncology Products, Potent Molecules and Peptides. He was Involved in many successful regulated inspections of USFDA, EUGMP, MHRA, MCC, TGA, ANVISA and BFRM. His past assignments include Quality leadership roles in Dr.Reddy's Laboratories Limited, Dabur Research Foundation, Aurobindo Pharma Limited etc.
08-Apr-2019 Caplin Point Laboratories' arm enters into license & supply agreement with Baxter <p align="justify">Caplin Point Laboratories' wholly owned Subsidiary -- Caplin Steriles has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable ANDAs.</p><p align="justify">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations. <br></p>
08-Apr-2019 Caplin Point Laboratories rises with its arm entering into license & supply agreement with Baxter <p align="justify">Caplin Point Laboratories is currently trading at Rs. 395.00, up by 7.70 points or 1.99% from its previous closing of Rs. 387.30 on the BSE.</p><p align="justify">The scrip opened at Rs. 388.40 and has touched a high and low of Rs. 397.95 and Rs. 388.00 respectively. So far 1162 shares were traded on the counter.</p><p align="justify">The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 622.55 on 06-Apr-2018 and a 52 week low of Rs. 304.75 on 29-Jan-2019.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 412.00 and Rs. 386.00 respectively. The current market cap of the company is Rs. 2974.16 crore.</p><p align="justify">The promoters holding in the company stood at 69.05%, while Institutions and Non-Institutions held 7.11% and 23.84% respectively.</p><p align="justify">Caplin Point Laboratories' wholly owned Subsidiary -- Caplin Steriles has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable ANDAs.</p><p align="justify">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.<br></p>
22-Mar-2019 Caplin Point Laboratories' arm gets USFDA's nod for Glycopyrrolate injection <p align="justify">Caplin Point Laboratories' Wholly Owned Subsidiary -- Caplin Steriles has been granted final approval by the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Glycopyrrolate injection USP, 0.2mg/ml (in 1 ml, 2 ml, 5 ml and 20 ml vial presentations), a generic therapeutic equivalent version of Robinul from West-Ward Pharmaceuticals International Limited. Glycopyrrolate is an anticholinergic drug.</p><p align="justify">According to IQVIA (IMS Health), Glycopyrrolate had US sales data of approximately $110.12 Million for the 12 month period ending December 2018. Caplin Steriles has developed and filed a total of 11 ANDAs, of which 7 are on its own (Caplin Steriles) and 4 with partners. </p><p align="justify">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations. <br></p>
22-Mar-2019 Caplin Point Laboratories' inches up with its arm getting USFDA's nod for Glycopyrrolate injection <p align="justify">Caplin Point Laboratories is currently trading at Rs. 405.35, up by 1.85 points or 0.46% from its previous closing of Rs. 403.50 on the BSE.</p><p align="justify">The scrip opened at Rs. 408.40 and has touched a high and low of Rs. 414.90 and Rs. 398.05 respectively. So far 30502 shares were traded on the counter.</p><p align="justify">The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 622.55 on 06-Apr-2018 and a 52 week low of Rs. 304.75 on 29-Jan-2019.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 437.90 and Rs. 398.05 respectively. The current market cap of the company is Rs. 3085.71 crore.</p><p align="justify">The promoters holding in the company stood at 69.05%, while Institutions and Non-Institutions held 7.11% and 23.84% respectively.</p><p align="justify">Caplin Point Laboratories' Wholly Owned Subsidiary -- Caplin Steriles has been granted final approval by the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Glycopyrrolate injection USP, 0.2mg/ml (in 1 ml, 2 ml, 5 ml and 20 ml vial presentations), a generic therapeutic equivalent version of Robinul from West-Ward Pharmaceuticals International Limited. Glycopyrrolate is an anticholinergic drug.</p><p align="justify">According to IQVIA (IMS Health), Glycopyrrolate had US sales data of approximately $110.12 Million for the 12 month period ending December 2018. Caplin Steriles has developed and filed a total of 11 ANDAs, of which 7 are on its own (Caplin Steriles) and 4 with partners. </p><p align="justify">Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.<br></p>

Enquiry For

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested